Form 4: Spero Therapeutics Director Ankit Mahadevia Granted 20,000 Restricted Stock Units

Spero Therapeutics, Inc. Director Ankit Mahadevia was granted 20,000 restricted stock units (RSUs) as part of his compensation, aligning his interests with shareholders.

Summary

• Ankit Mahadevia, a Director of Spero Therapeutics, Inc. (SPRO), was granted 20,000 shares of common stock in the form of restricted stock units (RSUs).
• The transaction date for this acquisition was June 12, 2025.
• Each RSU represents the right to receive one share of common stock upon vesting.
• The RSUs were granted at a price of $0.00 per unit, indicating they are part of an equity compensation plan.
• These RSUs are scheduled to vest on June 12, 2026, contingent upon Mr. Mahadevia's continued service to the company through that date.
• Following this transaction, Ankit Mahadevia beneficially owns a total of 709,866 shares of Spero Therapeutics common stock.
• This total beneficial ownership includes 65,817 shares held indirectly by the Mahadevia-Mehta Family Trust, for which Mr. Mahadevia serves as a trustee.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While not a major financial announcement, the grant of equity to a director signifies continued commitment and alignment of interests, which is generally viewed favorably by investors. It's a routine compensation event rather than a performance indicator.

Positives

• The grant of restricted stock units to a director aligns their financial interests with those of the company's shareholders, encouraging long-term commitment and performance.
• Equity compensation is a common and effective way to incentivize key personnel and retain talent.

Future Outlook

The vesting schedule for the restricted stock units on June 12, 2026, indicates an expectation of Ankit Mahadevia's continued service to Spero Therapeutics through that date.

Industry Context

The granting of restricted stock units to directors is a standard practice across various industries, particularly in biotechnology and pharmaceuticals, to attract and retain experienced board members and align their long-term interests with company performance and shareholder value.

Related Party Transactions

• Ankit Mahadevia's beneficial ownership includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which he is a trustee, indicating an indirect beneficial ownership.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with shareholders, potentially leading to more focused long-term decision-making aimed at increasing shareholder value.
• Employees: While not directly impacting all employees, such compensation practices for leadership can set a precedent for equity-based incentives within the company.

Next Steps

• The 20,000 restricted stock units are scheduled to vest on June 12, 2026, subject to the reporting person's continued service.

Key Dates

Keywords

Spero Therapeutics, SPRO, Form 4, SEC filing, insider transaction, restricted stock units, RSU, equity compensation, director compensation, Ankit Mahadevia